X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GSK PHARMA VENUS REMEDIES/
GSK PHARMA
 
P/E (TTM) x -534.0 56.7 - View Chart
P/BV x 0.2 10.1 1.5% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 VENUS REMEDIES   GSK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
GSK PHARMA
Mar-17
VENUS REMEDIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1433,838 3.7%   
Low Rs652,637 2.5%   
Sales per share (Unadj.) Rs324.2354.2 91.5%  
Earnings per share (Unadj.) Rs6.439.8 16.1%  
Cash flow per share (Unadj.) Rs40.642.9 94.6%  
Dividends per share (Unadj.) Rs030.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs366.0236.9 154.5%  
Shares outstanding (eoy) m12.3484.70 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.39.1 3.5%   
Avg P/E ratio x16.281.4 19.9%  
P/CF ratio (eoy) x2.675.5 3.4%  
Price / Book Value ratio x0.313.7 2.1%  
Dividend payout %075.4 0.0%   
Avg Mkt Cap Rs m1,282274,216 0.5%   
No. of employees `0000.94.7 19.2%   
Total wages/salary Rs m2514,830 5.2%   
Avg. sales/employee Rs Th4,430.16,387.0 69.4%   
Avg. wages/employee Rs Th278.01,028.3 27.0%   
Avg. net profit/employee Rs Th87.6717.1 12.2%   
INCOME DATA
Net Sales Rs m4,00030,000 13.3%  
Other income Rs m23728 3.1%   
Total revenues Rs m4,02330,728 13.1%   
Gross profit Rs m7854,190 18.7%  
Depreciation Rs m422263 160.3%   
Interest Rs m3440-   
Profit before tax Rs m424,655 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m-371,744 -2.1%   
Profit after tax Rs m793,368 2.3%  
Gross profit margin %19.614.0 140.5%  
Effective tax rate %-87.937.5 -234.6%   
Net profit margin %2.011.2 17.6%  
BALANCE SHEET DATA
Current assets Rs m2,60616,742 15.6%   
Current liabilities Rs m1,9807,202 27.5%   
Net working cap to sales %15.631.8 49.2%  
Current ratio x1.32.3 56.6%  
Inventory Days Days12852 247.6%  
Debtors Days Days4321 207.6%  
Net fixed assets Rs m5,3538,635 62.0%   
Share capital Rs m123847 14.6%   
"Free" reserves Rs m4,39319,222 22.9%   
Net worth Rs m4,51620,069 22.5%   
Long term debt Rs m1,61810 16,182.0%   
Total assets Rs m8,29130,038 27.6%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40 71,910.9%  
Sales to assets ratio x0.51.0 48.3%   
Return on assets %5.111.2 45.5%  
Return on equity %1.816.8 10.4%  
Return on capital %6.325.5 24.7%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m0528 0.0%   
Fx outflow Rs m7367,193 10.2%   
Net fx Rs m-736-6,665 11.0%   
CASH FLOW
From Operations Rs m9972,360 42.3%  
From Investments Rs m-4613,008 -15.3%  
From Financial Activity Rs m-571-5,108 11.2%  
Net Cashflow Rs m-35260 -13.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 1.8%  
FIIs % 0.6 23.8 2.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 15.4 431.2%  
Shareholders   20,121 102,036 19.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; SBI Up 3.7%(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 23, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS